The global Uveitis Treatment market size is expected to be worth around US$ 765.40 million by 2028, according to a new report by Vision Research Reports.
The global Uveitis Treatment market size was valued at US$ 500.03 million in 2020 and is anticipated to grow at a CAGR of 5.10% during forecast period 2021 to 2028.
Growth Factors
Rising prevalence of the condition is anticipated to drive the growth. For instance, according to The Ocular Immunology and Uveitis Foundation, around 43,000 new eye inflammation cases are being diagnosed each year in U.S.
Eye inflammation is also very prevalent among children. However, majority of the affected population ranges from 20 to 50 years of age. Growing geriatric population is also an important factor driving the growth of the market. Rise in number of R&D activities aiming at new drug development is another attribute increasing the demand for these treatments.
For instance, ADX-102 Ophthalmic Solution, by Aldeyra Therapeutics, Inc. is in Phase 2 clinical trial for the treatment of noninfectious anterior uveitis. The National Eye Institute is also engaged in conducting and supporting various research studies in this field. Increasing prevalence of infectious diseases is another contributing factor to the market growth. Infectious uveitis surrounds a significant array of potential pathogens, which is likely to pose immense threat to the people affected.
Report Highlights
On the basis of treatment type, corticosteroids held the largest market share in 2020, due to the fact that it is considered as the primary treatment for patients with noninfectious uveitis. Corticosteroid drugs are very useful for minimizing inflammation. Various types of corticosteroid eye drops available in the market are approved by the Food and Drug Administration (FDA). Ophthalmologists commonly recommend eye drops, oral medications, or injections of corticosteroids.
Corticosteroid implants are also increasingly gaining traction for people with chronic eye inflammation disorders. For instance, Retisert, manufactured by Bausch+Lomb is the first FDA approved surgical corticosteroid implant for treating noninfectious posterior uveitis in the U.S.
Monoclonal antibodies are anticipated to showcase lucrative CAGR over the forecast period owing to the rapid development of biologic drugs. Some of the commonly used biologic drugs include Infliximab, Interferon, Alefacept, Etanercept, Daclizumab, and Efalizumab among others.
Anterior uveitis led the market space in 2020 due to high prevalence of the condition among the adults as well as the young population. In addition, increasing research in this field highlights that this type of disease grows with age. There is high risk for people with untreated anterior uveitis leading to loss of vision as well as development of cataract, glaucoma, or retinal edema.
Posterior uveitis is expected to witness lucrative growth during the study period owing to the availability of various drugs. For instance, Trivaris, by Allergan is a corticosteroid used for its prevention. However, poor penetration of topical corticosteroids to the posterior portion of the eye is expected to restrain the uveitis treatment market.
Intermediate uveitis is anticipated to showcase significant growth over the forecast period because it facilitates prevention of permanent structural damage to vital ocular tissue. In addition, rising prevalence of various infectious diseases like tuberculosis, leprosy, Lyme’s disease, syphilis, toxocariasis, and whipple’s disease is expected to lead to rising cases of intermediate uveitis.
On the basis of cause segment, noninfectious uveitis generated significant market revenue in 2020 owing to the wide availability of various treatment options. Corticosteroids, antibiotics, immunosuppressants, and biologic drugs are some of the treatment types commonly used for noninfectious uveitis. Moreover, it is mostly prevalent in the developed regions of the world.
Infectious uveitis also held considerable market share in 2020 owing to the rising prevalence of infectious diseases in developing countries. It can affect various portions of the eye, from anterior to posterior. According to the American Academy of Ophthalmology, syphilis, sarcoidosis, and tuberculosis are found in most of the patients diagnosed with this condition.
On the basis of distribution channel, hospital pharmacies led the market in 2020 due to the availability of a wide array of options for the management of eye inflammation in the hospitals. Moreover, hospitals provide treatment and care to a large number of patients, thereby making hospital pharmacies a leading segment.
Online pharmacies is expected to witness significant CAGR over the forecast period due to the growing convenience in choosing from online websites that provide a wide range of drugs along with extensive product information. In addition, rising popularity of the e-commerce distribution channels offering prescribed medicines at discounted prices is another factor driving the growth.
North America led the market owing to the rising prevalence of noninfectious uveitis in U.S. In addition, advanced healthcare facilities and favorable reimbursement policies are attributed to propel the regional growth. A large number of drugs are commercially available in the U.S., which is further boosting the demand from the country.
Key Players
Allergan, Inc.; Bausch & Lomb Incorporated; Santen Pharmaceutical Co., Ltd; AbbVie Inc.; Novartis AG; Eyegate Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Eyepoint pharmaceuticals Inc.; and Alimera Sciences, Inc.
Market Segmentation
Treatment Type Outlook
Corticosteroids
Immunosuppressant
Monoclonal Antibodies
Cycloplegic Agents
Antibiotics
Antivirals
Antifungal
Analgesics
Disease Type Outlook
Anterior Uveitis
Posterior Uveitis
Intermediate Uveitis
Panuveitis
Cause Outlook
Infectious
Noninfectious
Distribution Channel Outlook
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Outlook
North America
The U.S.
Canada
Europe
Germany
The U.K.
France
Italy
Spain
Russia
Asia Pacific
Japan
China
India
South Korea
Australia
Singapore
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
The Uveitis Treatment market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Uveitis Treatment market for the base year 2020 and the forecast between 2021 and 2028. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Uveitis Treatment market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Uveitis Treatment market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Uveitis Treatment market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Uveitis Treatment capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Uveitis Treatment by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Uveitis Treatment market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2028. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Uveitis Treatment market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Uveitis Treatment market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Uveitis Treatment industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Uveitis Treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Uveitis Treatment market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Uveitis Treatment market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Uveitis Treatment market. These factors have benefited the growth of the global market for Uveitis Treatment. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Uveitis Treatment. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Uveitis Treatment are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Uveitis Treatment Market, By Treatment Type
7.1. Uveitis Treatment Market, By Treatment Type, 2020-2028
7.1.1. Corticosteroids
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Immunosuppressant
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Monoclonal Antibodies
7.1.3.1. Market Revenue and Forecast (2016-2028)
7.1.4. Cycloplegic Agents
7.1.4.1. Market Revenue and Forecast (2016-2028)
7.1.5. Antibiotics
7.1.5.1. Market Revenue and Forecast (2016-2028)
7.1.6. Antivirals
7.1.6.1. Market Revenue and Forecast (2016-2028)
7.1.7. Antifungal
7.1.7.1. Market Revenue and Forecast (2016-2028)
7.1.8. Analgesics
7.1.8.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Uveitis Treatment Market, By Disease Type
8.1. Uveitis Treatment Market, By Disease Type, 2020-2028
8.1.1. Anterior Uveitis
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. Posterior Uveitis
8.1.2.1. Market Revenue and Forecast (2016-2028)
8.1.3. Intermediate Uveitis
8.1.3.1. Market Revenue and Forecast (2016-2028)
8.1.4. Panuveitis
8.1.4.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Uveitis Treatment Market, By Cause
9.1. Uveitis Treatment Market, By Cause, 2020-2028
9.1.1. Infectious
9.1.1.1. Market Revenue and Forecast (2016-2028)
9.1.2. Noninfectious
9.1.2.1. Market Revenue and Forecast (2016-2028)
Chapter 10. Global Uveitis Treatment Market, By Capacitor
10.1. Uveitis Treatment Market, By Capacitor, 2020-2028
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2016-2028)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2016-2028)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2016-2028)
Chapter 11. Global Uveitis Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.1.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.1.3. Market Revenue and Forecast, By Cause (2016-2028)
11.1.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.1.5.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.1.5.3. Market Revenue and Forecast, By Cause (2016-2028)
11.1.5.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.1.6.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.1.6.3. Market Revenue and Forecast, By Cause (2016-2028)
11.1.6.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.2. Europe
11.2.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.2.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.2.3. Market Revenue and Forecast, By Cause (2016-2028)
11.2.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.2.5.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.2.5.3. Market Revenue and Forecast, By Cause (2016-2028)
11.2.5.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.2.6.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.2.6.3. Market Revenue and Forecast, By Cause (2016-2028)
11.2.6.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.2.7.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.2.7.3. Market Revenue and Forecast, By Cause (2016-2028)
11.2.7.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.2.8.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.2.8.3. Market Revenue and Forecast, By Cause (2016-2028)
11.2.8.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.3. APAC
11.3.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.3.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.3.3. Market Revenue and Forecast, By Cause (2016-2028)
11.3.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.3.5.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.3.5.3. Market Revenue and Forecast, By Cause (2016-2028)
11.3.5.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.3.6.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.3.6.3. Market Revenue and Forecast, By Cause (2016-2028)
11.3.6.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.3.7.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.3.7.3. Market Revenue and Forecast, By Cause (2016-2028)
11.3.7.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.3.8.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.3.8.3. Market Revenue and Forecast, By Cause (2016-2028)
11.3.8.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.4. MEA
11.4.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.4.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.4.3. Market Revenue and Forecast, By Cause (2016-2028)
11.4.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.4.5.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.4.5.3. Market Revenue and Forecast, By Cause (2016-2028)
11.4.5.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.4.6.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.4.6.3. Market Revenue and Forecast, By Cause (2016-2028)
11.4.6.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.4.7.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.4.7.3. Market Revenue and Forecast, By Cause (2016-2028)
11.4.7.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.4.8.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.4.8.3. Market Revenue and Forecast, By Cause (2016-2028)
11.4.8.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.5. Latin America
11.5.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.5.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.5.3. Market Revenue and Forecast, By Cause (2016-2028)
11.5.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.5.5.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.5.5.3. Market Revenue and Forecast, By Cause (2016-2028)
11.5.5.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, By Treatment Type (2016-2028)
11.5.6.2. Market Revenue and Forecast, By Disease Type (2016-2028)
11.5.6.3. Market Revenue and Forecast, By Cause (2016-2028)
11.5.6.4. Market Revenue and Forecast, By By Capacitor (2016-2028)
Chapter 12. Company Profiles
12.1. Allergan, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bausch & Lomb Incorporated
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Santen Pharmaceutical Co., Ltd
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AbbVie Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Eyegate Pharmaceuticals, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Regeneron Pharmaceuticals
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Eyepoint pharmaceuticals Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Alimera Sciences, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
Glossary of Terms